Neuronetics (STIM)
Nasdaq Market Closed
Neuronetics, Inc. is a commercial-stage medical technology company focused on neurohealth treatments for psychiatric conditions. Its principal product is the NeuroStar Advanced Therapy system, an office-based transcranial magnetic stimulation, or TMS, platform used by healthcare providers to treat major depressive disorder and certain other mental health indications. The therapy is non-invasive and does not rely on systemic drug exposure, making it an alternative for patients who have not achieved adequate results from conventional antidepressant treatment.
NeuroStar works by delivering targeted magnetic pulses to areas of the brain associated with mood regulation. The system is designed for use in outpatient clinical settings, giving psychiatrists and other trained providers a device-based treatment option that can be integrated into a broader mental health care program. Neuronetics supports the platform with equipment sales, treatment-session consumables, practice-development services, training, and patient-awareness initiatives.
The company operates through medical device and clinic services activities. Its device business is centered on expanding adoption of NeuroStar among physician practices and treatment centers, while the clinic services segment gives Neuronetics more direct exposure to patient care delivery and the economics of TMS treatment. As a listed medical technology company, Neuronetics sits at the intersection of mental health care, neuromodulation, and outpatient specialty medicine. Its growth depends on physician adoption, reimbursement coverage, patient demand, clinical evidence, and its ability to differentiate NeuroStar in a competitive market for depression therapies.
Last updated
- Market Cap
- 92.55M
- P/E
- —
- P/FCF
- —
- P/S
- 0.61
- Enterprise Value
- 140.63M
- Sector
- Industrials
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 92.55M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 140.63M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 6.98
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.61
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -5.38
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.93
- EPS
- -0.53
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -13.58M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -279.78%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -29.59%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 4.62
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.46
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.3
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.47
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.56M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.33
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 34.45M | 41.78M | 37.3M | 38.11M | 31.98M |
| Gross profit | 16.15M | 21.7M | 17.11M | 17.76M | 15.74M |
| Operating income | -9M | -5.04M | -7.32M | -8.06M | -11.01M |
| EBITDA | -8.25M | -4.28M | -6.48M | -7.11M | -10.1M |
| Net income | -10.79M | -7.16M | -9.05M | -10.12M | -12.68M |
| Basic EPS | -0.16 | -0.1 | -0.13 | -0.15 | -0.21 |
| Diluted EPS | -0.16 | -0.1 | -0.13 | -0.15 | -0.21 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 125.44M | 141.55M | 145.47M | 134.65M | 141.99M |
| Total liabilities | 108.38M | 115.31M | 114.11M | 103.14M | 102.46M |
| Total equity | 17.06M | 26.24M | 31.36M | 31.51M | 39.53M |
| Cash & equivalents | 13.21M | 28.13M | 27.97M | 10.97M | 20.22M |
| Current assets | 41.43M | 55.55M | 58.39M | 49.64M | 59.67M |
| Current liabilities | 28.29M | 30.52M | 28.94M | 27.8M | 24.84M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -9.42M | 908K | -785K | -3.5M | -16.99M |
| Investing cash flow | -172K | -216K | -114K | -252K | -219K |
| Financing cash flow | -5.58M | -1.03M | 17.9M | 1K | 18.98M |
| Change in cash | -15.17M | -337K | 17M | -3.76M | 1.77M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 8-K — Neuronetics, Inc. | View Filing | |
| edgar index | SD — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — MUIR GLENN P | View Filing | |
| form 4 | Form 4 — CASCELLA ROBERT | View Filing | |
| form 4 | Form 4 — CONLEY SHERYL L | View Filing | |
| form 4 | Form 4 — Rosengarten Megan | View Filing | |
| form 4 | Form 4 — Cucuz Sasha | View Filing | |
| form 4 | Form 4 — Cucuz Sasha | View Filing | |
| form 4 | Form 4 — Cucuz Sasha | View Filing | |
| form 4 | Form 4 — Amin Avinash | View Filing | |
| edgar index | SCHEDULE 13D/A — Neuronetics, Inc. | View Filing | |
| edgar index | 8-K — Neuronetics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4/A — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 3 — Neuronetics, Inc. | View Filing | |
| form 3 | Form 3 — BROWN FRANCIS X III | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 10-Q — Neuronetics, Inc. | View Filing | |
| edgar index | 8-K — Neuronetics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | EFFECT — Neuronetics, Inc. | View Filing | |
| edgar index | DEF 14A — Neuronetics, Inc. | View Filing | |
| edgar index | DEFA14A — Neuronetics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Neuronetics, Inc. | View Filing | |
| edgar index | CORRESP — Neuronetics, Inc. | View Filing | |
| edgar index | 8-K — Neuronetics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 3 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — REUVERS DANIEL L. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 144 — Neuronetics, Inc. | View Filing | |
| edgar index | 144 — Neuronetics, Inc. | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| form 4 | Form 4 — MACAN WILLIAM ANDREW | View Filing | |
| form 4 | Form 4 — Sullivan Keith J | View Filing | |
| form 4 | Form 4 — Pfanstiel Steven | View Filing | |
| form 4 | Form 4 — Pfanstiel Steven | View Filing | |
| edgar index | UPLOAD — Neuronetics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| edgar index | 3 — Neuronetics, Inc. | View Filing | |
| edgar index | 4 — Neuronetics, Inc. | View Filing | |
| form 3 | Form 3 — Chernett Jorey | View Filing | |
| form 4 | Form 4 — Chernett Jorey | View Filing | |
| edgar index | 10-K — Neuronetics, Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free